title: Quantitative T-wave analysis predicts 1 year prognosis and benefit from early invasive treatment in the FRISC II study population.
abstract: OBJECTIVE
  To investigate the prognostic value of T-wave abnormalities in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS), and whether such ECG changes may predict benefit from an early coronary angiography. Although ST-segment changes are considered the most important ECG feature in NSTE-ACS, T-wave abnormalities are the most common ECG finding. We hypothesize that a new quantitative approach to T-wave analysis could improve the prognostic value of this ECG abnormality.
  
  
  RESULTS
  Quantitative T-wave analysis was performed on the admission ECG in 1609 patients with NSTE-ACS. Nine different categories of T-wave abnormality were analysed for their prognostic value concerning clinical outcome in patients not randomized to early coronary angiography. Also, the presence of one category (i.e. T-wave abnormality in > or =6 leads) was analysed for its predictive value concerning benefit from early coronary angiography. The combined study endpoint was death or myocardial infarction at 1 year follow-up. Patients with > or =6 leads with abnormal T-waves and concomitant ST-segment depression had a higher risk when not receiving early coronary angiography (24 vs. 12%, respectively; P=0.003), but could be brought to the same level of risk as the remaining patients with this treatment. For non-invasively treated patients five different categories of T-wave abnormality were significantly associated with an adverse outcome.
  
  
  CONCLUSIONS
  New quantitative T-wave analysis of the admission ECG gives additional predictive information concerning clinical outcome and identifies patients who benefit from early coronary angiography.
authors.affiliation: The Heart Center, Department of Medicine B, H:S Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, DK-2100, Copenhagen, Denmark. mdiloujacobsen@dadlnet.dk
authors.forename: Michael D
authors.initials: MD
authors.lastname: Jacobsen
authors.forename: Galen S
authors.initials: GS
authors.lastname: Wagner
authors.forename: Lene
authors.initials: L
authors.lastname: Holmvang
authors.forename: Frederic
authors.initials: F
authors.lastname: Kontny
authors.forename: Lars
authors.initials: L
authors.lastname: Wallentin
authors.forename: Steen
authors.initials: S
authors.lastname: Husted
authors.forename: Eva
authors.initials: E
authors.lastname: Swahn
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Ståhle
authors.forename: Rolf
authors.initials: R
authors.lastname: Steffensen
authors.forename: Peter
authors.initials: P
authors.lastname: Clemmensen
mesh_terms: D000368:Aged; D001026:Coronary Artery Bypass / Q000401:mortality; D017985:Dalteparin / Q000627:therapeutic use; D018572:Disease-Free Survival; D004562:Electrocardiography; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000401:mortality* / Q000628:therapy; D011379:Prognosis
chemical_list: D005343:Fibrinolytic Agents; D017985:Dalteparin